Clinical Trial Update: A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and exploratory efficacy of 1.0 mg Luminate (Alg-1001) for non-exudative (dry) age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Age-related Macular Degeneration

Drugs mentioned

• Luminate

Snippet

Sponsor: Allegro Ophthalmics, LLC | Conditions: Dry Age-related Macular Degeneration | Phase 2 | Status: COMPLETED